The anti-leukemia activity of TOPK inhibition was also validated in primary blast cells obtained from three patients with AML with FLT3-ITD mutation who had relapsed after treatment with a potent FLT3 inhibitor (AC220 [quizartinib]) (Supplementary Table S2, Figure 4A). The gene discussed is FLT3; the disease is acute myeloid leukemia.